Shire Uses Foresight To Expand In Ophthalmology
This article was originally published in The Pink Sheet Daily
Executive Summary
Shire acquired Foresight Biotherapeutics for $300 million, gaining a late-stage drug for pink eye that will be a commercial complement to lifitegrast.
You may also be interested in...
New Shire CEO Has Big Ophthalmology Plans; SARcode Sets The Stage
With its third acquisition this year, Shire gains Phase III Lifitegrast in development for dry eye disease. It expects to launch the product in the U.S. in 2016.
Merck & Co. Remains 'Very Confident' In TIGIT
Despite initial underwhelming competitive data on the cancer target, Merck said it is expanding its investment behind its anti-TIGIT drug vibostolimab. Roche updated investors on its program too.
From Hallelujah To Headwind: Pfizer's COVID-19 Franchise Hits The Downturn
Pfizer expects Comirnaty and Paxlovid revenues to be drastically lower this year after pushing 2022 revenues over $100bn. Management said 2023 would be a transition year for the company.